| Author | Malan, Niel | |
| Author | Su, Jun | |
| Author | Mancini, Marco | |
| Author | Yang, Rong | |
| Author | Wirtz, Victoria | |
| Author | Absalon, Judith | |
| Author | McGrath, Donnie | |
| Author | CASTLE Study Team | |
| Access date | 2018-11-22T15:28:20Z | |
| Available date | 2018-11-22T15:28:20Z | |
| Document date | 2010 | |
| Citation | MALAN, Niel. et al. Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study. AIDS Care, v. 22, n. 6, p. 677-686, 2010. | pt_BR |
| ISSN | 0954-0121 | pt_BR |
| URI | https://www.arca.fiocruz.br/handle/icict/30165 | |
| Description | Presente no CASTLE Study tem: Beatriz Grinsztejn (Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil). | pt_BR |
| Language | eng | pt_BR |
| Rights | restricted access | pt_BR |
| Title | Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study | pt_BR |
| Type | Article | |
| DOI | 10.1080/09540120903334641 | |
| Abstract | Most ritonavir-boosted protease inhibitor (PI)-based antiretroviral regimens offer comparable levels of virological efficacy. Thus, the tolerability of the regimen becomes a distinguishing factor with implications for patient quality of life (QoL), treatment adherence, and clinical outcome. This article describes results from the CASTLE study (comparing once-daily atazanavir/ritonavir [ATV/RTV] with twice-daily lopinavir/ritonavir [LPV/RTV], both in combination with fixed-dose tenofovir/emtricitabine, in treatment-naive HIV-infected patients) and an evaluation of the impact of gastrointestinal (GI) complications of treatment on patient QoL, as measured by the irritable bowel syndrome (IBS) QoL questionnaire (IBS-QoL). Changes in IBS-QoL from baseline over time (to week 24) were classified as: "Improvement" (> or =2-point positive change from baseline), "No change" (<2-point change), or "Worsening" (> or =2-point negative change). Data were collected on GI adverse events (AEs) and use of GI medications. Of the 599 patients with IBS-QoL-evaluable data through week 24, fewer patients in the ATV/RTV group than in the LPV/RTV group experienced grade 2-4 treatment-related GI AEs including diarrhea (3% versus 10%), nausea (5% versus 7%), and vomiting (<1% on both arms). Nearly three times as many patients receiving LPV/RTV used GI medications. ATV/RTV was associated with an increase in overall IBS-QoL scores and more patients receiving ATV/RTV than LPV/RTV experienced improvement in IBS-QoL through week 24. In contrast to LPV/RTV, ATV/RTV treatment was associated with earlier and more positive improvements in QoL scores across CD4 sub-groups. Differences in the health-related QoL profile between ATV/RTV and LPV/RTV may be important when selecting PI-based antiretroviral regimens. | pt_BR |
| Affilliation | Triple M Research. Central, Port Elizabeth, South Africa. | pt_BR |
| Affilliation | Bristol-Myers Squibb. Research and Development. Wallingford, CT, USA. | pt_BR |
| Affilliation | Bristol-Myers Squibb. Research and Development. Wallingford, CT, USA. | pt_BR |
| Affilliation | Bristol-Myers Squibb. Research and Development. Wallingford, CT, USA. | pt_BR |
| Affilliation | Bristol-Myers Squibb. Research and Development. Wallingford, CT, USA. | pt_BR |
| Affilliation | Bristol-Myers Squibb. Research and Development. Wallingford, CT, USA. | pt_BR |
| Affilliation | Bristol-Myers Squibb. Research and Development. Wallingford, CT, USA. | pt_BR |
| Subject | HIV-1 | pt_BR |
| Subject | Atazanavir | pt_BR |
| Subject | GI tolerability | pt_BR |
| Subject | Health-related quality of life | pt_BR |
| Embargo date | 2025-08-30 | |
